Gene Silencing Market Analysis, Growth and Trends 2034
Global Gene Silencing Market Growth, Size, Trends Analysis- By Product & Service, By Application, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Sep-2025 | Report ID: HLCA25280 | Pages: 1 - 262 | Formats*: |
| Category : Healthcare | |||
Global Gene Silencing Market Introduction and Overview
According to SPER Market Research, the Global Gene Silencing Market is estimated to reach USD 36923.47 million by 2034 with a CAGR 14.05%.
The report includes an in-depth analysis of the Global Gene Silencing Market, including market size and trends, product mix, Applications, and supplier analysis. The global Gene Silencing Market, valued at USD 9,916.3 million in 2024, is projected to grow at a CAGR of 14.05% from 2025 to 2034. The gene silencing industry is growing due to the rising prevalence of genetic disorders and chronic diseases, driving demand for targeted therapies like RNA interference (RNAi) and antisense oligonucleotides (ASOs). These technologies offer precise inhibition of disease-causing genes, making them promising for previously hard-to-treat conditions. Advances in delivery systems, such as lipid nanoparticles and conjugate-based methods, have improved the stability, specificity, and safety of gene silencing agents. This has broadened their use beyond liver diseases to include neurological and cardiovascular disorders. Additionally, collaborations among biotech firms, pharmaceutical companies, and academia are accelerating development and overcoming regulatory hurdles.
By Product & Service:
The products segment currently leads the gene silencing industry, driven by ongoing advancements in RNA interference, antisense oligonucleotides, and CRISPR-Cas technologies. Innovations in delivery methods—such as lipid nanoparticles, GalNAc conjugates, and viral vectors—have improved therapeutic stability, specificity, and effectiveness. Rising demand for targeted treatments for rare genetic disorders, cancer, and neurodegenerative diseases continues to boost product development. Companies are expanding their pipelines, with several therapies progressing through clinical stages or gaining regulatory approval. Meanwhile, the services segment is growing rapidly as developers increasingly outsource tasks like assay development and vector design to specialized providers.
By Application:
Drug discovery and development currently lead the gene silencing market, as researchers utilize RNA interference, antisense oligonucleotides, and CRISPR-Cas technologies to target and silence disease-related genes, accelerating the creation of new therapies. Collaborations among biotech companies, academic institutions, and pharmaceutical firms are fostering innovation, enabling faster transitions from early research to clinical trials. Meanwhile, therapeutics manufacturing is experiencing strong growth, driven by rising demand for gene silencing treatments. Investments in automation, single-use systems, and advanced purification methods, along with partnerships with contract manufacturers and evolving regulatory support, are enhancing large-scale production capabilities.
By End Use:
Pharmaceutical and biotechnology companies lead the gene silencing market, driven by expanding R&D pipelines aimed at addressing unmet medical needs. Strategic collaborations, licensing deals, and acquisitions are accelerating innovation and product development. Regulatory incentives like orphan drug status and fast-track approvals further support growth. Meanwhile, contract research and manufacturing organizations are expected to see the fastest growth, fueled by increasing demand for specialized expertise and scalable production. Companies are outsourcing preclinical studies, clinical trials, and manufacturing to CROs and CMOs, who offer advanced technologies and services to streamline development and meet growing therapeutic demand.
Regional Insights:
North America holds the largest share of the gene silencing market, driven by strong investments in biotechnology, a robust healthcare infrastructure, and ongoing advancements in RNA interference and antisense oligonucleotide technologies. Major pharmaceutical companies collaborate with academic and research institutions to develop cutting-edge therapies, further propelling growth. The region also benefits from high awareness of rare diseases and early adoption of advanced medical technologies. In Asia Pacific, the market is growing rapidly due to increasing healthcare innovation, awareness of genetic disorders, and rising collaborations between local biotech firms and global pharmaceutical companies, particularly in countries like China and Japan.
Market Competitive Landscape:
The global Gene Silencing Market is moderately consolidated, with several prominent players shaping the industry. Key companies include: Agilent Technologies, Bio-Rad Laboratories, Bio-Techne, Danaher, GenScript, Illumina, Merck KGaA, New England Biolabs, Inc., Revvity, Inc., Thermo Fisher Scientific, Inc.
Recent Developments:
The completion of the gene therapy collaboration between Biogen and Ginkgo Bioworks in January 2024 is expected to boost future demand for gene therapies.
In December 2023, the Swiss Agency for Therapeutic Products approved Libmeldy for the treatment of early-onset metachromatic leukodystrophy. This approval underscores the growing recognition and acceptance of gene therapy as an effective approach for treating genetic disorders.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product & Service, By Application, By End Use |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Agilent Technologies, Bio-Rad Laboratories, Bio-Techne, Danaher, GenScript, Illumina, Merck KGaA, New England Biolabs, Inc., Revvity, Inc., Thermo Fisher Scientific, Inc. |
Key Topics Covered in the Report
- Global Gene Silencing Market Size (FY’2021-FY’2034)
- Overview of Global Gene Silencing Market
- Segmentation of Global Gene Silencing Market By Product & Service (Products, Services)
- Segmentation of Global Gene Silencing Market By Application (Drug Discovery & Development, Therapeutics Manufacturing, Agricultural Applications, Others)
- Segmentation of Global Gene Silencing Market By End Use, (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROs & CMOs, Others)
- Statistical Snap of Global Gene Silencing Market
- Expansion Analysis of Global Gene Silencing Market
- Problems and Obstacles in Global Gene Silencing Market
- Competitive Landscape in the Global Gene Silencing Market
- Details on Current Investment in Global Gene Silencing Market
- Competitive Analysis of Global Gene Silencing Market
- Prominent Players in the Global Gene Silencing Market
- SWOT Analysis of Global Gene Silencing Market
- Global Gene Silencing Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Gene Silencing Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Gene Silencing Market
7.Global Gene Silencing Market, By Product & Service, (USD Million) 2021-2034
7.1.Products
7.1.1.RNAi7.1.2.CRISPR-Cas97.1.3.Antisense Oligonucleotides
7.2.Services
8.Global Gene Silencing Market, By Application, (USD Million) 2021-2034
8.1.Drug Discovery & Development
8.1.1.Neurology8.1.2.Oncology8.1.3.Infectious Diseases8.1.4.Metabolic Diseases8.1.5.Others
8.2.Therapeutics Manufacturing8.3.Agricultural Applications8.4.Others
9.Global Gene Silencing Market, By End Use, (USD Million) 2021-2034
9.1.Pharmaceutical & Biotechnology Companies9.2.Academic & Research Institutes9.3.CROs & CMOs9.4.Others
10.Global Gene Silencing Market, (USD Million) 2021-2034
10.1.Global Gene Silencing Market Size and Market Share
11.Global Gene Silencing Market, By Region, 2021-2034 (USD Million)
11.1.Asia-Pacific
11.1.1.Australia11.1.2.China11.1.3.India11.1.4.Japan11.1.5.South Korea11.1.6.Rest of Asia-Pacific
11.2.Europe
11.2.1.France11.2.2.Germany11.2.3.Italy11.2.4.Spain11.2.5.United Kingdom11.2.6.Rest of Europe
11.3.Middle East and Africa
11.3.1.Kingdom of Saudi Arabia11.3.2.United Arab Emirates11.3.3.Qatar11.3.4.South Africa11.3.5.Egypt11.3.6.Morocco11.3.7.Nigeria11.3.8.Rest of Middle-East and Africa
11.4.North America
11.4.1.Canada11.4.2.Mexico11.4.3.United States
11.5.Latin America
11.5.1.Argentina11.5.2.Brazil11.5.3.Rest of Latin America
12.Company Profile
12.1.Agilent Technologies
12.1.1.Company details12.1.2.Financial outlook12.1.3.Product summary12.1.4.Recent developments
12.2.Bio-Rad Laboratories
12.2.1.Company details12.2.2.Financial outlook12.2.3.Product summary12.2.4.Recent developments
12.3.Bio-Techne
12.3.1.Company details12.3.2.Financial outlook12.3.3.Product summary12.3.4.Recent developments
12.4.Danaher
12.4.1.Company details12.4.2.Financial outlook12.4.3.Product summary12.4.4.Recent developments
12.5.GenScript
12.5.1.Company details12.5.2.Financial outlook12.5.3.Product summary12.5.4.Recent developments
12.6.Illumina
12.6.1.Company details12.6.2.Financial outlook12.6.3.Product summary12.6.4.Recent developments
12.7.Merck KGaA
12.7.1.Company details12.7.2.Financial outlook12.7.3.Product summary12.7.4.Recent developments
12.8.New England Biolabs, Inc.
12.8.1.Company details12.8.2.Financial outlook12.8.3.Product summary12.8.4.Recent developments
12.9.Revvity, Inc.
12.9.1.Company details12.9.2.Financial outlook12.9.3.Product summary12.9.4.Recent developments
12.10.Thermo Fisher Scientific, Inc.
12.10.1.Company details12.10.2.Financial outlook12.10.3.Product summary12.10.4.Recent developments
12.11.Others
13.Conclusion
14.List of Abbreviations
15.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Gene Silencing Market is projected to reach USD 36923.47 million by 2034, growing at a CAGR of 14.05% during the forecast period.
Gene Silencing Market size from 2025. The Market is expected to reach USD 36923.47 million by 2034, at a CAGR of 14.05% during the forecast period.
Gene Silencing Market CAGR of 14.05% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Gene Silencing Market size is USD 36923.47 million from 2025 to 2034.
Gene Silencing Market covered By Product & Service, By Application, By End Use
The North America is anticipated to have the highest Market share in the Gene Silencing Market.
Agilent Technologies, Bio-Rad Laboratories, Bio-Techne, Danaher, GenScript, Illumina, Merck KGaA, New England Biolabs, Inc., Revvity, Inc., Thermo Fisher Scientific, Inc.
The report includes an in-depth analysis of the Global Gene Silencing Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
